What is ETON's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.43B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ETON?

P/E (TTM) is 112.98 and 52-week range is $14.27 to $66.37 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ETON figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ETON?

The company profile lists revenue (TTM) near $92M, net income (TTM) near $11M, EPS (TTM) near $0.39 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Eton Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Deer Park, Illinois, US, 28.6M shares outstanding, ISIN US29772L1089 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Eton Pharmaceuticals Inc

$ETON

Health Care · Pharmaceuticals

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 44 full-time employees. The company went IPO on 2018-11-09. The firm has over 11 commercial rare disease products: KHINDIVI, INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, HEMANGEOL, PKU GOLIKE, IMPAVIDO, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The firm has four additional product candidates in late-stage development: Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjectors. INCRELEX (mecasermin) is used to treat children who are very short for their age because their bodies do not make enough insulin-like growth factor-1 (IGF-1). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. NITISINONE is a prescription medicine used to treat adults and children with a hereditary disease called tyrosinemia type 1 (HT-1). The firm also has licensed United States rights to a rare disease product candidate ASN-001 (timolol topical gel).

Employees

Website

etonpharma.com/

IPO

2018-11-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US29772L1089

Headquarters

Deer Park, Illinois, US

Shares outstanding

28.6M

NAICS sector

Manufacturing

Institutional ownership

70.41%

Browse other companiesFree AI scores and summaries for more stocks